New York State Common Retirement Fund Mersana Therapeutics, Inc. Transaction History

New York State Common Retirement Fund

  • $74.9 Billion
  • Q3 2025

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2025
BUY
$1.23 - $2.25 $45,799 - $83,778
37,235 New
37,235 $70,000
Q2 2024

Oct 08, 2025
BUY
$2.0 - $4.45 $74,470 - $165,695
37,235 New
37,235 $74,000
Q2 2024

Jul 31, 2024
BUY
$2.0 - $4.45 $160 - $356
80 Added 0.22%
37,235 $75,000
Q1 2024

Oct 08, 2025
BUY
$2.16 - $5.94 $80,254 - $220,700
37,155 New
37,155 $166,000
Q1 2024

May 07, 2024
SELL
$2.16 - $5.94 $203 - $558
-94 Reduced 0.25%
37,155 $166,000
Q4 2023

Oct 08, 2025
BUY
$1.11 - $2.34 $41,346 - $87,162
37,249 New
37,249 $86,000
Q4 2023

Feb 01, 2024
SELL
$1.11 - $2.34 $118 - $250
-107 Reduced 0.29%
37,249 $86,000
Q3 2023

Oct 08, 2025
BUY
$1.06 - $3.91 $39,597 - $146,061
37,356 New
37,356 $47,000
Q3 2023

Nov 07, 2023
BUY
$1.06 - $3.91 $384 - $1,419
363 Added 0.98%
37,356 $47,000
Q2 2023

Oct 08, 2025
BUY
$3.08 - $9.55 $113,938 - $353,283
36,993 New
36,993 $121,000
Q2 2023

Aug 07, 2023
SELL
$3.08 - $9.55 $354 - $1,098
-115 Reduced 0.31%
36,993 $122,000
Q1 2023

Oct 08, 2025
SELL
$4.0 - $7.02 $75,492 - $132,488
-18,873 Reduced 33.71%
37,108 $152,000
Q1 2023

May 02, 2023
SELL
$4.0 - $7.02 $75,492 - $132,488
-18,873 Reduced 33.71%
37,108 $153,000
Q4 2022

Oct 08, 2025
BUY
$5.65 - $7.86 $316,292 - $440,010
55,981 New
55,981 $328,000
Q4 2022

Jan 30, 2023
SELL
$5.65 - $7.86 $113 - $157
-20 Reduced 0.04%
55,981 $328,000
Q3 2022

Nov 08, 2022
BUY
$4.63 - $8.0 $33,780 - $58,368
7,296 Added 14.98%
56,001 $379,000
Q2 2022

Aug 04, 2022
SELL
$2.84 - $5.0 $335 - $590
-118 Reduced 0.24%
48,705 $225,000
Q1 2022

May 05, 2022
SELL
$3.74 - $6.63 $11,163 - $19,790
-2,985 Reduced 5.76%
48,823 $195,000
Q4 2021

Feb 02, 2022
SELL
$5.48 - $9.86 $306 - $552
-56 Reduced 0.11%
51,808 $322,000
Q3 2021

Nov 02, 2021
SELL
$8.56 - $14.47 $64,893 - $109,697
-7,581 Reduced 12.75%
51,864 $489,000
Q2 2021

Aug 02, 2021
BUY
$13.28 - $18.07 $148,005 - $201,390
11,145 Added 23.07%
59,445 $807,000
Q4 2020

Feb 08, 2021
BUY
$16.84 - $27.59 $106,092 - $173,817
6,300 Added 15.0%
48,300 $1.29 Million
Q2 2020

Aug 07, 2020
BUY
$5.24 - $23.4 $79,648 - $355,680
15,200 Added 56.72%
42,000 $983,000
Q1 2020

May 06, 2020
BUY
$4.41 - $9.28 $66,591 - $140,128
15,100 Added 129.06%
26,800 $156,000
Q3 2019

Nov 07, 2019
SELL
$1.54 - $4.2 $38,500 - $105,000
-25,000 Reduced 68.12%
11,700 $18,000
Q2 2019

Aug 09, 2019
BUY
$3.84 - $6.4 $94,464 - $157,440
24,600 Added 203.31%
36,700 $149,000
Q1 2018

May 10, 2018
BUY
$13.56 - $18.48 $119,328 - $162,624
8,800 Added 266.67%
12,100 $191,000
Q4 2017

Feb 13, 2018
BUY
$14.95 - $19.9 $34,385 - $45,770
2,300 Added 230.0%
3,300 $54,000
Q3 2017

Nov 06, 2017
BUY
$14.8 - $18.06 $14,800 - $18,060
1,000
1,000 $17,000

Others Institutions Holding MRSN

# of Institutions
13
Shares Held
22.2M
Call Options Held
0
Put Options Held
0
View Full List

About Mersana Therapeutics, Inc.

MRSN Quotes by TradingView
  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $2.67B
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email